ArticleAmerican journal of human genetics1996
Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma.
Article in American journal of human genetics, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Pooled it
- Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis.European journal of cancer (Oxford, England : 1990) · 2012Pooled it
- GST polymorphisms are associated with hepatocellular carcinoma risk in Chinese population.World journal of gastroenterology · 2011Pooled it
- Mode of action-based risk assessment of genotoxic carcinogens.Archives of toxicology · 2020Review
- Chronic and Acute Toxicities of Aflatoxins: Mechanisms of Action.International journal of environmental research and public health · 2020Review
- Environmental Exposures and Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2013Review
- Global DNA methylation in a population with aflatoxin B1 exposure.Epigenetics · 2013Article
- Review
- Current understanding on aflatoxin biosynthesis and future perspective in reducing aflatoxin contamination.Toxins · 2012Review
- The role of aflatoxins in hepatocellular carcinoma.Hepatitis monthly · 2012Article
- Sulforaphane- and phenethyl isothiocyanate-induced inhibition of aflatoxin B1-mediated genotoxicity in human hepatocytes: role of GSTM1 genotype and CYP3A4 gene expression.Toxicological sciences : an official journal of the Society of Toxicology · 2010Article
- Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma.World journal of hepatology · 2010Article
- Pharmacogenomics: a tool for improving cancer chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2008Review
- Personalized exposure assessment: promising approaches for human environmental health research.Environmental health perspectives · 2005Review
- Determinants of formation of aflatoxin-albumin adducts: a seven-township study in Taiwan.British journal of cancer · 2002Article
- Glutathione-S-Transferase M1 null genotype in autoimmune hepatitis.Digestive diseases and sciences · 2001Article
- Article
- Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers.British journal of cancer · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
This study was carried out to elucidate the effect of glutathione S-transferase (GST) Ml and Tl polymorphisms on the aflatoxin-related hepatocarcinogenesis among chronic carriers of hepatitis B surface antigen (HBsAg). A total of 32 newly diagnosed hepatocellular carcinoma (HCC) cases and 73 age-matched controls selected from a cohort of 4,841 chronic HBsAg carriers who had been followed for 5 years were studied. The level of aflatoxin B1 (AFB1)-albumin adducts in their serum samples collected at the recruitment was examined by competitive enzyme-linked immunosorbance assay, and genotypes of GST M1 and T1 were determined by PCR. There was a dose-response relationship between serum level of AFB1-albumin adducts and risk of HCC. The biological gradients between serum AFB1-albumin adducts level and HCC risk were observed among chronic HBsAg carriers who had null genotypes of GST M1 and/or T1 but not among those who had non-null genotypes. The multivariate-adjusted odds ratios of developing HCC for those who had low and high serum levels of AFB1-albumin adducts compared with those who had a undetectable adduct level as the referent (odds ratio = 1.0) were 4.1 and 12.4, respectively, for HBsAg carriers with null GST M1 genotype (P < .01, on the basis of the significance test for trend); 0.7 and 1.4 for those with non-null GST Ml genotype (P = .98); 1.8 and 10.2 for those with null GST T1 genotype (P < .05); and 1.3 and 0.8 for those with non-null GST T1 genotype (P = .93). The interaction between serum AFB1-albumin adduct level and polymorphisms of GST M1 and T1 was at marginal statistical significance levels (.05 < P < .10).
Indexed as
Identifiers
8659516PMC1915093W1561521870What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.